Trial Profile
Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Piflufolastat F18 (Primary)
- Indications Prostate cancer
- Focus Diagnostic use; Proof of concept
- 05 May 2020 Status changed from active, no longer recruiting to completed.
- 10 May 2019 Planned End Date changed from 1 Apr 2018 to 1 Apr 2020.
- 10 May 2019 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2020.